NGS: MET exon 14 mutations detected in 28/933 NSCLC patients (3.0%); 61% deletions, 39% point mutations; 29% of patients also had EGFR copy gain; 71% of patients had at least 1 mutation in TP53 or MDM2IHC: c-MET expressed more in stage IV samples with MET exon 14 mutations than stage I-III samples with MET exon 14 mutationsqRT-PCR: MET exon 14 skipping occurred in 96% of samples tested. Here, EGFR is linked to non-small cell lung carcinoma.